ITALY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) MARKET ANALYSIS

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market – Insights

The market opportunities for key players to enter into this market are high owing to less competition and increasing demand for peptide receptor radionuclide therapy in the Italy market. Moreover, increasing incidence of cancer in Italy is directly contributing to demand for PRRT therapy. These factors are creating growth opportunities for companies to focus on research and development of new drugs. As per the Italian Association of Medical Oncology’s report, in April 2019, 71,000 new cases were diagnosed with new additional cancer cases.

The Italy Peptide Receptor Radionuclide Therapy (PRRT) Market was valued at US$ 3.6 million in 2019, and is expected to witness a CAGR of 9.2%over the forecast period (2019 – 2027).

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Share (%) Analysis, By Drug Type, 2019

To learn more about this report, Request sample copy

Source: Coherent Market Insights Analysis (2019)

Increasing incidence of pancreatic cancer, as well as availability of reimbursement for cancer drug is another factor contributing to the market growth.

Increasing incidence of pancreatic cancer in Europe region is expected to support growth of the market over the forecast period. For instance, according to United European Gastroenterology report in Europe region, there was a 5% increase in the number of pancreatic cancer cases during the years 1990 to 2016.

The European Medicines Agency (EMA) plays a central role in facilitating development and authorization of medicines for rare diseases, which are termed as ‘orphan medicines’. In Italy, prices of ODs (Orphan Drugs) and reimbursement by the National Health Service is set through negotiation between the Italian Medicines Agency (AIFA), and pharmaceutical companies. Reimbursement of 38% is available for ODs in Italy which includes peptide receptor radionuclide therapy (PRRT).

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market - Restraints

High cost associated with cancer treatment, which include diagnosis and therapeutic treatment, is a major factor that is expected to restrain growth of the market. For instance, as per the Economist Intelligence Unit Limited’s 2016 report, lung cancer treatment cost has become a burden on the economy in Italy. In 2013, it was estimated that total cost for treatment of lung cancer reached around US$ 18.31 billion.

Currently, only one approved PRRT drug is available in the Italy market, and is used in the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumor (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, lack of availability of different drugs is another major factor restraining growth of the market.

Moreover, high cost of treatment is expected to restrain growth of the market. For instance, Novartis Company’s drug, Lutathera, is priced at US$ 99,900 for a full course of treatment comprising four infusions.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

To learn more about this report, Request sample copy

 Source: Coherent Market Insights Analysis (2019)

Key player operating in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is Novartis International AG.